Chengdu Ucello Biotechnology Co., Ltd.
Clinical trials sponsored by Chengdu Ucello Biotechnology Co., Ltd., explained in plain language.
-
Engineered immune cells take on lupus in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called CD19/BCMA CAR-T cell therapy for adults with refractory systemic lupus erythematosus (SLE) that hasn't improved with standard treatments. About 24 participants will receive a single infusion of their own engineered immune cells …
Early phase 1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests whether a patient's own immune cells, modified to target a protein called Claudin18.2, can safely treat advanced solid tumors. Eighteen adults whose cancer has not responded to standard treatments will receive the modified cells and be monitored for s…
Early phase 1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC